SCHEMBL5708128

SCHEMBL5708128

CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]34OC4C[C@@]21C

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.79
HIF1A Q16665 9/20 0.70
PGR P06401 6/20 0.70
LMNA P02545 5/20 0.70
CYP3A4 P08684 4/20 0.70
AR P10275 4/20 0.70
ALDH1A1 P00352 2/20 0.70
POLB P06746 1/20 0.70
KMT2A Q03164 2/20 0.56
MAPK1 P28482 1/20 0.55
NR3C1 P04150 5/20 0.53
HRH1 P35367 1/20 0.53
CNR1 P21554 2/20 0.51
KCNH2 Q12809 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
USP2 O75604 1/20 0.51
MAPT P10636 1/20 0.51
CYP2C9 P11712 1/20 0.51
TBXA2R P21731 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24525578 1.00 KDM4E (0.79) KDM4EHIF1APGRLMNACYP3A4
SCHEMBL24852454 1.00 KDM4E (0.79) KDM4EHIF1APGRLMNACYP3A4
SCHEMBL5708123 1.00 KDM4E (0.79) KDM4EHIF1APGRLMNACYP3A4
SCHEMBL3170728 0.88 KDM4E (1.00) KDM4EHIF1APGRLMNACYP3A4
SCHEMBL3170744 0.88 KDM4E (1.00) KDM4EHIF1APGRLMNACYP3A4
SCHEMBL5259047 0.88 KDM4E (1.00) KDM4EHIF1APGRLMNACYP3A4
SCHEMBL3170735 0.88 KDM4E (1.00) KDM4EHIF1APGRLMNACYP3A4
SCHEMBL11368251 0.88 KDM4E (0.63) KDM4EHIF1APGRLMNACYP3A4
SCHEMBL6152790 0.86 KDM4E (0.76) KDM4EHIF1APGRLMNACYP3A4
SCHEMBL5943277 0.85 KDM4E (0.80) KDM4EHIF1APGRLMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1422235-B1 STEREOSELECTIVE METHOD OF PRODUCING 6ALPHA-FLUOROPREGNANES AND INTERMEDIARIES RAGACTIVES SL (ES) 2006-10-04 EP disclosed
US-20040181055-A1 Stereoselective process for the production of 6alpha-fluorpregnanes and intermediates RAGACTIVES, S.L. 2004-09-16 US disclosed
EP-1422235-A1 STEREOSELECTIVE METHOD OF PRODUCING 6ALPHA-FLUOROPREGNANES AND INTERMEDIARIES Ragactives, S.L. (ES) 2004-05-26 EP disclosed
EP-0105650-B1 PROCESS FOR PREPARING 9,11-EPOXY STEROIDS FROM 9 ALPHA-SUBSTITUTED-11-HYDROXY STEROIDS THE UPJOHN COMPANY (US) 1988-06-08 EP disclosed
US-4442035-A Acyclic amine epoxide process THE UPJOHN COMPANY (US) 1984-04-10 US disclosed
US-4255331-A 3-Acetoxy-9β-11β-epoxy-dienes and the preparation of the corresponding 6α-halogen-4-ene-3-ones PROCHEM ESTABLISHMENT (LI) 1981-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181055-A1 Stereoselective process for the production of 6alpha-fluorpregnanes and intermediates NR5A1, SRD5A2, SRD5A1 KDM4E 1969/4885HIF1A 1830/4885PGR 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.